Role of Fibrocytes in Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease
- Registration Number
- NCT01196832
- Lead Sponsor
- University Hospital, Bordeaux
- Brief Summary
Chronic obstructive pulmonary disease (COPD) is a frequent airway disease characterized by both bronchial inflammation and remodelling.
Bronchial mucosa is infiltrated by macrophages, neutrophils and lymphocytes. In addition, the number of eosinophils can be also increased during exacerbation.
Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of COPD and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 115
- Patients: diagnostic of Chronic obstructive pulmonary disease (COPD) exacerbation.
- Control group: subjects without any history of lung disease and with normal lung function testing. Subjects will be separated in 2 sub-groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex.
- Written informed consent
- Subject without any social security or health insurance
- Asthma, lung fibrosis or idiopathic pulmonary hypertension
- Chronic viral infections (hepatitis, HIV)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of circulating blood fibrocytes 2 months Sampling of blood in Chronic obstructive pulmonary disease patients
- Secondary Outcome Measures
Name Time Method Chemotactism of blood fibrocytes Day 1 and at 2 months Sampling of blood
Differenciation of blood fibrocytes Day 1 and at 2 months Sampling of blood
Number of exacerbation 12 months after V2 Annual decline of ventilatory function 12 months after V2 Mortality 12 months after V2 Characterization of fibrocytes Day 1 and at 2 months Sampling of blood
Trial Locations
- Locations (1)
CHU de Bordeaux
🇫🇷Pessac, France
CHU de Bordeaux🇫🇷Pessac, France